Aquestive Therapeutics Share Price Today
(NASDAQ: AQST)

Name: Aquestive Therapeutics Share Price Today (NASDAQ: AQST) - Aquestive Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Aquestive Therapeutics share price is $3.07 & ₹267.38 as on 5 Feb 2025, 2.30 'hrs' IST

$3.07

▲

0.18

(6.23%)

Market is closed - opens 8 PM, 05 Feb 2025

View live Aquestive Therapeutics share price in Dollar and Rupees. Guide to invest in Aquestive Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Aquestive Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Aquestive Therapeutics share price movements

Today's Low: $2.89
Today's High: $3.08
$3.07
5.86%
Downside
Day's Volatility :6.02%
Upside
0.16%
52 Weeks Low: $2.24
52 Weeks High: $6.23
$3.07
27.04%
Downside
52 Weeks Volatility :64.04%
Upside
50.72%

Aquestive Therapeutics (AQST) Returns

Period	Aquestive Therapeutics Inc	Index (Russel 2000)
3 Months	-43.0%	0.0%
6 Months	-15.74%	0.0%
1 Year	3.58%	0.0%
3 Years	11.15%	-11.7%

Aquestive Therapeutics (AQST) Key Statistics

in dollars & INR

Previous Close	$2.89
Open	$2.9
Today's High	$3.075
Today's Low	$2.89
Market Capitalization	$275.4M
Today's Volume	$1.1M
52 Week High	$6.23
52 Week Low	$2.24
Revenue TTM	$58.9M
EBITDA	$-20.0M
Earnings Per Share (EPS)	$-0.45
Profit Margin	-59.75%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	0.0%

How to invest in Aquestive Therapeutics Stock (AQST) from India?

It is very easy for Indian residents to invest directly in Aquestive Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Aquestive Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Aquestive Therapeutics or AQST on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Aquestive Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Aquestive Therapeutics shares which would translate to 0.284 fractional shares of Aquestive Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Aquestive Therapeutics, in just a few clicks!

Returns in Aquestive Therapeutics (AQST) for Indian investors in Rupees

The Aquestive Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Aquestive Therapeutics investment value today

Current value as on today

₹1,14,900

Returns

₹14,900

(+14.9%)

Returns from Aquestive Therapeutics Stock

₹10,036 (+10.04%)

Dollar Returns

₹4,865 (+4.86%)

Indian investors sentiment towards Aquestive Therapeutics (AQST)

32%

Period: Jan 5, 2025 to Feb 4, 2025. Change in 30 Days versus previous period

Search interest for Aquestive Therapeutics Stock from India on INDmoney has increased by 32% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Aquestive Therapeutics

Bratton Capital Management, L.P.
10.76%
BlackRock Inc
6.39%
VR Adviser, LLC
6.09%
Vanguard Group Inc
4.68%
Franklin Resources Inc
3.03%
MPM Oncology Impact Management LP
1.97%

Analyst Recommendation on Aquestive Therapeutics

Buy

92%Buy

7%Hold

0%Sell

Based on 14 Wall street analysts offering stock ratings for Aquestive Therapeutics(by analysts ranked 0 to 5 stars)

Based on 14 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Aquestive Therapeutics Stock (AQST)

What analysts predicted

Upside of 252.88%

Target:

$10.83

Current:

$3.07

Insights on Aquestive Therapeutics Stock (Ticker Symbol: AQST)

Price Movement
In the last 3 months, AQST stock has moved down by -43.9%
Decreasing Revenue
Revenue is down for the last 2 quarters, 20.09M → 13.54M (in $), with an average decrease of 32.6% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -2.74M → -11.50M (in $), with an average decrease of 319.3% per quarter
AQST vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 89.1% return, outperforming this stock by 79.2%
AQST vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 161.1% return, outperforming this stock by 149.5%
Price to Sales
ForAQST every $1 of sales, investors are willing to pay $4.0, whereas for Intra-cellular Therapies, Inc., the investors are paying $20.9 for every $1 of sales.

AQST Aquestive Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$67.4M	↑ 0.77%
Net Income	$-61.4M	↑ 586.3%
Net Profit Margin	-91.02%	↓ 77.66%

	FY19	Y/Y Change
Revenue	$52.6M	↓ 21.98%
Net Income	$-72.7M	↑ 18.38%
Net Profit Margin	-138.11%	↓ 47.09%

	FY20	Y/Y Change
Revenue	$45.8M	↓ 12.85%
Net Income	$-65.4M	↓ 10.04%
Net Profit Margin	-142.56%	↓ 4.45%

	FY21	Y/Y Change
Revenue	$50.8M	↑ 10.87%
Net Income	$-90.0M	↑ 37.75%
Net Profit Margin	-177.12%	↓ 34.56%

	FY22	Y/Y Change
Revenue	$47.7M	↓ 6.2%
Net Income	$-60.2M	↓ 33.14%
Net Profit Margin	-126.26%	↑ 50.86%

	FY23	Y/Y Change
Revenue	$50.6M	↑ 6.09%
Net Income	$-7.9M	↓ 86.93%
Net Profit Margin	-15.56%	↑ 110.7%

	Q2 FY23	Q/Q Change
Revenue	$13.2M	↑ 18.92%
Net Income	$-5.8M	↓ 130.0%
Net Profit Margin	-43.74%	↓ 217.14%

	Q3 FY23	Q/Q Change
Revenue	$13.0M	↓ 1.8%
Net Income	$-2.0M	↓ 64.87%
Net Profit Margin	-15.65%	↑ 28.09%

	Q4 FY23	Q/Q Change
Revenue	$13.2M	↑ 1.57%
Net Income	$-8.1M	↑ 298.57%
Net Profit Margin	-61.42%	↓ 45.77%

	Q1 FY24	Q/Q Change
Revenue	$12.1M	↓ 8.73%
Net Income	$-12.8M	↑ 58.16%
Net Profit Margin	-106.43%	↓ 45.01%

	Q2 FY24	Q/Q Change
Revenue	$20.1M	↑ 66.76%
Net Income	$-2.7M	↓ 78.6%
Net Profit Margin	-13.66%	↑ 92.77%

	Q3 FY24	Q/Q Change
Revenue	$13.5M	↓ 32.62%
Net Income	$-11.5M	↑ 319.27%
Net Profit Margin	-84.99%	↓ 71.33%

	FY18	Y/Y Change
Profit	$46.4M	↓ 1.39%

	FY19	Y/Y Change
Profit	$32.2M	↓ 30.56%

	FY20	Y/Y Change
Profit	$32.9M	↑ 1.98%

	FY21	Y/Y Change
Profit	$35.8M	↑ 8.99%

	FY22	Y/Y Change
Profit	$28.3M	↓ 21.06%

	FY23	Y/Y Change
Profit	$29.8M	↑ 5.15%

	Q2 FY23	Q/Q Change
Profit	$6.6M	↑ 3.55%

	Q3 FY23	Q/Q Change
Profit	$8.2M	↑ 23.85%

	Q4 FY23	Q/Q Change
Profit	$8.5M	↑ 3.94%

	Q1 FY24	Q/Q Change
Profit	$7.7M	↓ 10.12%

	Q2 FY24	Q/Q Change
Profit	$15.6M	↑ 103.2%

	Q3 FY24	Q/Q Change
Profit	$9.1M	↓ 41.53%

	FY18	Y/Y Change
Operating Cash Flow	$-13.0M	↓ 323.06%
Investing Cash Flow	$-1.8M	↓ 11.8%
Financing Cash Flow	$58.0M	↑ 1214.79%

	FY19	Y/Y Change
Operating Cash Flow	$-60.2M	↑ 363.47%
Investing Cash Flow	$-663.0K	↓ 63.65%
Financing Cash Flow	$49.6M	↓ 14.53%

	FY20	Y/Y Change
Operating Cash Flow	$-45.5M	↓ 24.5%
Investing Cash Flow	$-517.0K	↓ 22.02%
Financing Cash Flow	$28.5M	↓ 42.63%

	FY21	Y/Y Change
Operating Cash Flow	$-33.0M	↓ 27.45%
Investing Cash Flow	$-913.0K	↑ 76.6%
Financing Cash Flow	$30.1M	↑ 5.81%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-7.9M	↓ 189.69%
Investing Cash Flow	$-826.0K	↑ 41200.0%
Financing Cash Flow	$4.3M	↓ 146.57%

Aquestive Therapeutics Technicals Summary

Sell

Neutral

Buy

Aquestive Therapeutics is currently in a neutral trading position according to technical analysis indicators.

Aquestive Therapeutics (AQST) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Aquestive Therapeutics Inc	-12.42%	-15.74%	3.58%	11.15%	-27.02%
Intra-cellular Therapies, Inc.	55.53%	72.74%	81.47%	149.54%	495.46%
Haleon Plc Spon Ads	0.32%	-1.35%	13.13%	27.94%	27.94%
Zoetis Inc.	3.64%	-6.94%	-12.34%	-14.17%	23.79%
Neurocrine Biosciences Inc.	9.68%	4.14%	4.99%	85.26%	44.35%
Viatris Inc.	-7.62%	-2.82%	-7.15%	-27.65%	-32.44%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Aquestive Therapeutics Inc	NA	NA	NA	-0.42	0.0	-0.16	NA	-0.5
Intra-cellular Therapies, Inc.	NA	NA	0.0	-0.71	-0.1	-0.07	NA	10.8
Haleon Plc Spon Ads	28.7	28.7	1.68	0.36	0.07	0.04	0.02	1.82
Zoetis Inc.	32.18	32.18	2.66	5.89	0.47	0.15	0.01	11.59
Neurocrine Biosciences Inc.	40.03	40.03	0.35	6.59	0.16	0.12	NA	26.87
Viatris Inc.	224.4	NA	0.07	2.68	-0.04	0.02	0.04	16.58

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Aquestive Therapeutics Inc	Buy	$275.4M	-27.02%	NA	-59.75%
Intra-cellular Therapies, Inc.	Buy	$13.5B	495.46%	NA	-14.07%
Haleon Plc Spon Ads	Buy	$42.8B	27.94%	28.7	10.75%
Zoetis Inc.	Buy	$77.1B	23.79%	32.18	26.55%
Neurocrine Biosciences Inc.	Buy	$15.2B	44.35%	40.03	17.21%
Viatris Inc.	Hold	$13.5B	-32.44%	224.4	-5.87%

About Aquestive Therapeutics

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Organization	Aquestive Therapeutics
Employees	135
CEO	Mr. Daniel Barber
Industry	Health Technology

Management People of Aquestive Therapeutics

Name	Title
Mr. Daniel Barber	CEO, President & Director
Mr. A. Ernest Toth Jr.	Chief Financial Officer
Ms. Lori J. Braender BSBA, Esq., J.D.	Chief Legal Officer, Chief Compliance Officer &Secretary
Ms. Cassie Jung	Chief Operating Officer
Dr. Stephen Wargacki Ph.D.	Chief Science Officer
Ms. Sherry Korczynski	Senior Vice President of Sales & Marketing
Mr. Peter E. Boyd	Senior Vice President of Information Technology & Human Resources
Dr. Gary H. Slatko M.D., MBA	Chief Medical Officer
Dr. Carl N. Kraus M.D.	Chief Medical Officer
Mr. Robert Charles Arnold	VP of Finance, Controller & Assistant Secretary

Important FAQs about investing in AQST Stock from India :

What is Aquestive Therapeutics share price today?

Aquestive Therapeutics share price today stands at $3.07, Open: $2.90 ; Previous Close: $2.89 ; High: $3.08 ; Low: $2.89 ; 52 Week High: $6.23 ; 52 Week Low: $2.24.

The stock opens at $2.90, after a previous close of $2.89. The stock reached a daily high of $3.08 and a low of $2.89, with a 52-week high of $6.23 and a 52-week low of $2.24.

Can Indians buy Aquestive Therapeutics shares?

Yes, Indians can invest in the Aquestive Therapeutics (AQST) from India.

With INDmoney, you can buy Aquestive Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Aquestive Therapeutics at zero transaction cost.

How can I buy Aquestive Therapeutics shares from India?

It is very easy to buy Aquestive Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Aquestive Therapeutics (AQST) be purchased?

Yes, you can buy fractional shares of Aquestive Therapeutics with INDmoney app.

What are the documents required to start investing in Aquestive Therapeutics stocks?

To start investing in Aquestive Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.